Year End Report 2014
February 27, 2015
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Year End Report for 2014.
- Revenue for the 4th quarter 2014 was SEK 24.2 (22.8) million, and for the full year 57.6 (68.2) million
- Operating result for the period amounted to SEK 8.5 (1.7) million, and for the full year to 5.3 (8.5) million
- EBITDA for the period amounted to SEK 8.6 (1.8) million, and for the full year to 5.7 (8.7) million
- Net result for the period amounted to SEK 7.9 (0.9) million, and for the full year to 3.7 (6.6) million
- Cash flow for the period was SEK 9.9 (12.5) million, and for the full year 2.8 (11.8) million
- Cash and cash equivalents at the end of the period amounted to SEK 35.9 (33.1) million
Significant events during the quarter
- In October 2014, Sobi decided to place the phase 1 study of SOBI002 on clinical hold as adverse events were observed in the first-in-human study. All subjects that have been dosed with SOBI002 are well. Sobi is now working to understand these adverse events
- In November 2014 Nordic Nanovector ASA and Affibody AB announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radioimmunotherapies (RIT) for multiple myeloma, a collaboration backed by a Eurostars grant
Other significant events during 2014
- The first patient was included in a PET Imaging Study of HER2 Expression in Breast Cancer at Herlev University Hospital
- Investor AB acquired all HealthCap’s shares in Affibody
Significant events after the end of the reporting period
- No significant events were reported after the end of the reporting period
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.
Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, Daiichi-Sankyo, Daewoong and Thermo Fisher.
Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden.
Further information can be found at: www.affibody.com